WST93AUSA

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (Canceled).

6(Currently Amended). The A peptide or polypeptide according to claim 3 which is selected from the group consisting of: ASAVNLYIPTQE SEQ ID NO:84, VYLAPGRISRDY SEQ ID NO:85, VYLAPGRFSRDY SEQ ID NO:86, CTSHWGVLSQRR SEQ ID NO:87, RVLSPESYLGPS SEQ ID NO:88, VGNGVLMGRRG SEQ ID NO:90, RVLSPESYLGPA SEQ ID NO:92, GNCRYIGLRQFG SEQ ID NO:93, DIRVEPGGGYTH SEQ ID NO:94, APIHTYTGRARG SEQ ID NO:96, and RHTCVRSCGHDR SEQ ID NO:97 which binds to a selectin and blocks binding between said selectin and a Lewis SA-Lea or SA-LeX antigen.

Claim 7(Canceled).

8(Currently Amended). The A peptide or polypeptide according to claim 3, wherein said Lewis antigen is SA-Len-and said peptide or polypeptide is selected from the group consisting of VGIWSVVSEGSR SEQ ID NO:102, RCSVGVPFTMES SEQ ID NO:103, QDGVWEHVLEGG, SEQ ID NO:104, DLWDWVVGKPAG SEQ ID NO:1, VELSGRGGLCTW SEQ ID NO:105, VIGAASHDEDVD SEQ ID NO:106, TIEPVLAEMFMG SEQ ID NO:107, DKETFELGLFDR SEQ ID NO:108, FSGVRGVYESRT SEQ ID NO:109, PDDAPMHSTRVE SEQ ID NO:110, STGLMVDFLEPG SEQ ID NO:91, AKTFGLEHGCEA SEQ ID NO:95,

WST93AUSA

GGTVEVWSIKGG SEQ ID NO:115, DHFSQAGSSNHH SEQ ID NO:116,
DDPVTPVIDFGK SEQ ID NO:117, and RDGLIDFVVAGT SEQ ID NO:118 which
binds to a selectin and blocks binding between said selectin and a Lewis SA-Le^a or SALeX antigen.

Claims 9-60 (Canceled).

61(Currently Amended). A-modified The peptide or polypeptide according to claim 6, which comprises a mimicking a carbohydrate ligand of an adhesion molecule in a physiologically acceptable carrier, wherein said ligand is a Lowis antigen and wherein said modification is selected from the group consisting of (i) use of one or more D amino acids, (ii) insertion of a moiety which can provide a net positive charge at the N-terminus of said peptide or polypeptide, (iii) insertion of a spacer of greater than 3 amino acids interposed between the N- and C-termini to cyclize the peptide, (iv) insertion of a free hydroxyl on the C-terminus, (v) insertion of an amide or imide on the C-terminus, and (vi) insertion of a sequence of one or up to about 15 additional amino acids on the C-terminus.

Claims 62-64 (Canceled).

65(New). The peptide or polypeptide according to claim 8, which comprises a modification selected from the group consisting of (i) use of one or more D amino acids, (ii) insertion of a moiety which can provide a net positive charge at the N-terminus of said peptide or polypeptide, (iii) insertion of a spacer of greater than 3 amino acids interposed between the N- and C-termini to cyclize the peptide, (iv) insertion of a free hydroxyl on the C-terminus, (v) insertion of an amide or imide on the C-terminus, and (vi) insertion of a sequence of one or up to about 15 additional amino acids on the C-terminus.